After nearly a decade of mass tort litigation in New Jersey, Roche Holding AG won an appeals court ruling on Monday that could help the company stamp out claims that it didn’t adequately warn the public of side effects associated with its acne treatment Accutane.
An intermediate appeals court in Trenton reversed a 2010 verdict that Roche should pay $2.1 million to California resident Gillian Gaghan, who developed inflammatory bowel disease after using Accutane to treat her severe acne. Gaghan’s doctor had testified that he would have prescribed the drug even if Roche’s warning label had contained all the disclosures proposed by Gaghan’s lawyers. Based on that testimony, the appeals court decided the case in favor of Roche on the grounds that Gaghan couldn’t possibly show that the allegedly inadequate warnings caused her IBD.
This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.
To view this content, please continue to their sites.
Not a Lexis Subscriber?
Subscribe Now
Not a Bloomberg Law Subscriber?
Subscribe Now
LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.
For questions call 1-877-256-2472 or contact us at [email protected]
